雷氏银盏隔姜灸联合补火生土法干预缓解期溃疡性结肠炎的效果评价

许宝才; 陈伟

doi:10.16766/j.cnki.issn.1674-4152.002469

雷氏银盏隔姜灸联合补火生土法干预缓解期溃疡性结肠炎的效果评价

doi: 10.16766/j.cnki.issn.1674-4152.002469

许宝才,
陈伟^,

衢州市中医医院消化科, 浙江衢州 324002

基金项目:

全国中医临床特色技术传承骨干人才培训项目国中医药人教函〔2019〕36号

浙江省中医药科学研究基金项目 2018ZA129

浙江省中医药科学研究基金项目 2020ZB289

浙江省中医药科学研究基金项目 2021ZB324

浙江省科技计划项目 2015C33274

详细信息

通讯作者:
陈伟, E-mail: qzcwcw@139.com

中图分类号: R574.62 R245.8
计量
- 文章访问数: 145
- HTML全文浏览量: 60
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-21
- 网络出版日期: 2022-09-05

Evaluation of the effect of LEI's Yinzhan ginger moxibustion combined with Buhuo Shengtu therapy on ulcerative colitis in the remission stage

XU Bao-cai,
CHEN Wei^,

Department of Gastroenterology, Quzhou Hospital of Traditional Chinese Medicine, Quzhou, Zhejiang 324002, China

摘要

摘要: 目的评价雷氏银盏隔姜灸联合补火生土法治疗缓解期溃疡性结肠炎(ulcerativecolitis, UC)的效果及可能的作用机制。方法选择2017年1月—2020年6月衢州市中医医院消化科、肛肠科门诊及住院的73例UC患者，按照随机数字表法分为观察组(36例)和对照组(37例)。观察组采用雷氏银盏隔姜灸联合补火生土法治疗，对照组采用美沙拉嗪治疗，疗程为4周，评价2组干预效果及作用机制。结果治疗后观察组疗效优于对照组(Z=2.352，P=0.019)。治疗后观察组主要中医症状积分低于对照组[(26.04±5.37)分vs. (32.23±6.45)分，P＜0.05]。治疗后观察组改良梅奥评分低于对照组[(5.32±1.07)分vs. (6.75±1.56)分，P＜0.05]。治疗后观察组血清CRP、TNF-α、IL-17水平低于对照组(均P＜0.05)。治疗后观察组NK、CD4⁺与CD4⁺/CD8⁺水平高于对照组，CD8⁺水平低于对照组(均P＜0.05)。治疗后观察组IgG、IgM水平明显低于对照组(均P＜0.05)。结论雷氏银盏隔姜灸联合补火生土法干预治疗缓解期UC的效果明确，其作用机制可能与调节肠道炎症、免疫功能有关。
- 溃疡性结肠炎 /
- 银盏隔姜灸 /
- 脾肾阳虚 /
- 雷氏医学
Abstract: Objective To evaluate the effect and possible mechanism of LEI's Yinzhan ginger-padded moxibustion combined with Buhuo Shengtu therapy in the treatment of ulcerative colitis (UC) in the remission stage. Methods From January 2017 to June 2020, 73 UC patients in the Department of Gastroenterology, Department of Anus and Intestine of Quzhou Hospital of Traditional Chinese Medicine were randomly divided into two groups according to random number table method. The observation group(n=36) was treated with LEI's Yinzhan ginger-padded moxibustion combined with Buhuo Shengtu therapy, whereas the control group(n=37) was treated with mesalazine. The course of treatment was 4 weeks. The intervention effect and mechanism of the two groups were evaluated. Results After treatment, the efficacy of the observation group was better than that of the control group (Z=2.352, P=0.019). The symptom score of the observation group was lower than that of the control group [(26.04±5.37) scores vs. (32.23±6.45) scores, P < 0.05]. The Mayo score in the observation group was lower than that in the control group [(5.32±1.07) scores vs. (6.75±1.56) scores, P < 0.05]. The levels of serum inflammatory factors (CRP, TNF-α and IL-17) were lower in the observation group than in the control group (all P < 0.05). The levels of NK, CD4⁺ and CD4⁺/CD8⁺ were higher in the observation group than in the control group (all P < 0.05). The IgG and IgM values were significantly lower in the observation group than those in the control group (all P < 0.05). Conclusion LEI's Yinzhan ginger-padded moxibustion combined with Buhuo Shengtu therapy has a definite effect on the treatment of UC in the remission stage, and its mechanism may be related to the regulation of intestinal inflammation and immune function.
- Ulcerative colitis /
- Yinzhan ginger-padded moxibustion /
- Yang deficiency of the spleen and kidney /
- LEI's Medicine

HTML全文

表 1 2组溃疡性结肠炎患者临床疗效比较[例(%)]

Table 1. Comparison of clinical efficacy between two groups of ulcerative colitis patients [cases (%)]

组别	例数	完全缓解	有效	无效	总有效
观察组	36	23(63.89)	10(27.78)	3(8.33)	33(91.67)
对照组	37	15(40.54)	11(29.73)	11(29.73)	26(70.27)
注：2组疗效比较，Z=2.352，P=0.019。

下载: 导出CSV

表 2 2组溃疡性结肠炎患者中医主要症状积分比较(x±s，分)

Table 2. Comparison of TCM main symptom scores between two groups of ulcerative colitis patients (x±s, scores)

组别	例数	治疗前	治疗后	t值	P值
观察组	36	36.48±4.75	26.04±5.37	-8.737	< 0.001
对照组	37	38.62±5.13	32.23±6.45	-4.691	< 0.001
t值		-1.848	-4.461
P值		0.069	< 0.001

下载: 导出CSV

表 3 2组溃疡性结肠炎患者Mayo评分比较(x±s，分)

Table 3. Comparison of Mayo score between two groups of ulcerative colitis patients(x±s, scores)

组别	例数	治疗前	治疗后	t值	P值
观察组	36	8.51±1.69	5.32±1.07	-9.569	< 0.001
对照组	37	8.64±1.52	6.75±1.56	-5.278	< 0.001
t值		-0.346	-4.555
P值		0.730	< 0.001

下载: 导出CSV

表 4 2组溃疡性结肠炎患者血清炎症因子水平比较(x±s)

Table 4. Comparison of serum inflammatory factors between two groups of patients with ulcerative colitis(x±s)

组别	例数	CRP(mg/L)		TNF-α(ng/mL)		IL-17(μg/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	36	20.49±5.13	2.15±0.42^a	44.01±6.21	26.42±4.65^a	33.36±7.05	14.97±2.85^a
对照组	37	19.67±4.83	6.48±0.51^a	43.78±5.98	34.98±5.42^a	33.29±6.84	21.37±3.34^a
t值		0.703	-39.539	0.161	-7.233	0.043	8.796
P值		0.484	< 0.001	0.872	< 0.001	0.966	< 0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 5 2组溃疡性结肠炎患者外周血T淋巴细胞亚群变化比较(x±s)

Table 5. Comparison of T lymphocyte subsets in peripheral blood between two groups of patients with ulcerative colitis(x±s)

组别	例数	NK(%)		CD4⁺(%)		CD8⁺(%)		CD4⁺/CD8⁺
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	36	10.35±2.21	18.36±2.37^a	35.65±5.36	48.22±5.26^a	39.64±3.08	27.21±2.75^a	1.23±0.31	1.65±0.25^a
对照组	37	10.38±2.19	14.76±2.09^a	35.83±5.43	39.89±5.19^a	39.78±3.16	35.41±2.38^a	1.25±0.37	1.42±0.29^a
t值		-0.058	6.888	-0.142	6.810	-0.191	-13.634	-0.250	3.625
P值		0.954	< 0.001	0.887	< 0.001	0.848	< 0.001	0.803	0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 6 2组溃疡性结肠炎患者免疫球蛋白变化比较(x±s，g/L)

Table 6. Comparison of immunoglobulin changes between two groups of ulcerative colitis patients (x±s, g/L)

组别	例数	IgG		IgM		IgA
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	36	13.01±2.64	7.13±1.24^a	1.61±0.54	0.93±0.34^a	2.30±1.25	2.25±1.14
对照组	37	12.64±2.31	8.87±1.32^a	1.59±0.42	1.21±0.43^a	2.29±1.18	2.26±1.07
t值		0.638	-5.801	0.175	-3.081	0.035	-0.039
P值		0.526	< 0.001	0.861	0.003	0.972	0.969
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

参考文献(16)

[1]	程慧, 冯晓莹, 徐华. 炎症性肠病242例临床分析[J]. 中国医科大学学报, 2017, 46(11): 1039-1041. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201711018.htm CHENG H, FENG X Y, XU H. Clinical analysis of 242 inflammatory bowel disease cases[J]. Journal of China Medical University, 2017, 46(11): 1039-1041. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201711018.htm
[2]	田洁, 王亮, 徐宁. 美沙拉嗪、枯草杆菌二联活菌肠溶胶囊联合用于轻、中度溃疡性结肠炎患者的疗效观察[J]. 实用药物与临床, 2019, 23(3): 296-299. https://www.cnki.com.cn/Article/CJFDTOTAL-LYLC201903021.htm TIAN J, WANG L, XU N. Efficacy of mesalazine combined with Bacillus subtilis enteric-coated capsules in patients with mild to moderate ulcerative colitis[J]. Drugs for use and clinical practice, 2019, 23(3): 296-299. https://www.cnki.com.cn/Article/CJFDTOTAL-LYLC201903021.htm
[3]	毕文静, 柳越冬. 中医治疗慢性非特异性溃疡性结肠炎的研究近况[J]. 辽宁中医杂志, 2017, 44(2): 422-425. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201702068.htm BI W J, LIU Y D. Recent advances in the study of traditional Chinese medicine in the treatment of chronic non-specific ulcerative colitis[J]. Liaoning J Tradit Chin Med, 2017, 44(2): 422-425. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201702068.htm
[4]	邱根祥, 许宝才, 方昉, 等. 衢州雷氏医学源流与学术特色初探[J]. 浙江中医杂志, 2017, 52(11): 781-783. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJZZ201711004.htm QIU G Y, XU B C, FANG F, et al. The origin and academic characteristics of Lehrer' s medicine in Quzhou[J]. Zhejiang Journal of Traditional Chinese medicine, 2017, 52(11): 781-783. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJZZ201711004.htm
[5]	中华医学会消化学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201809007.htm Inflammatory bowel disease group, digestive society, Chinese Medical Association. Consensus on inflammatory bowel disease diagnosis and treatment (Beijing, 2018)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9): 796-813. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201809007.htm
[6]	中国中西医结合学会消化系统疾病专业委员会. 溃疡性结肠炎中西医结合诊疗共识意见[J]. 中国中西医结合消化杂志, 2018, 26(2): 105-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201802001.htm The gastrointestinal disease committee of the Chinese Society of Integrated Traditional Chinese and Western medicine. A ulcerative colitis consensus on the diagnosis and treatment of integrated Chinese and Western medicine[J]. 中国中西医结合消化杂志, 2018, 26(2): 105-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201802001.htm
[7]	WANG X R, ZHU Y G, ZHANG M L, et al. The shifted balance beteen circulating follicular regulatory T cells and follicular helper T cells in patients with ulcerative colitis[J]. Clin Sci, 2017, 131(24): 2933-2945. doi: 10.1042/CS20171258
[8]	张冰, 谢晶日, 孙涛. 中药内服与灌肠治疗活动期溃疡性结肠炎的临床疗效[J]. 中华全科医学, 2019, 17(2): 284-287. doi: 10.16766/j.cnki.issn.1674-4152.000662 ZHANG B, XIE J R, SUN T. Clinical efficacy of oral Chinese medicine and enema in the treatment of active ulcerative colitis[J]. Chinese general practice, 2019, 17(2): 284-287. doi: 10.16766/j.cnki.issn.1674-4152.000662
[9]	丁栋, 李佳妮, 齐冉, 等. 溃疡性结肠炎的研宄进展[J]. 药学研究, 2017, 36(7): 404-408. DING D, LI J N, QI R, et al. Progress in ulcerative colitis research[J]. Pharmaceutical Research, 2017, 36(7): 404-408.
[10]	翁湘涛, 胡月, 廖柳, 等. 参苓白术散加减对比西药治疗溃疡性结肠炎的疗效和安全性meta分析[J]. 中国实验方剂学杂志, 2017, 23(10): 205-210. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201710034.htm WEN X T, HU Y, LIAO L, et al. Meta-analysis of the efficacy and safety of Shenlingbaizhu powder in the treatment of ulcerative colitis disease[J]. Chinese Journal of experimental prescription, 2017, 23(10): 205-210. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201710034.htm
[11]	肖迅, 张燕. 中药有效成分/有效部位治疗溃疡性结肠炎的研究进展[J]. 中药药理与临床, 2017, 33(3): 219-223. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL201703067.htm XIAO X, ZHANG Y. Research progress of effective components and active parts of Chinese herbal medicine in the treatment of ulcerative colitis[J]. Pharmacology and clinic of Chinese materia medica, 2017, 33(3): 219-223. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL201703067.htm
[12]	许宝才, 陈刚, 吴世泉. 陈伟主任医师论治脾胃病的学术经验[J]. 中国中医急症, 2018, 27(10): 1838-1841. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJZ201810045.htm XU B C, CHEN G, WU S Q. Professor Chen Wei' s academic experience in treating spleen and stomach diseases[J]. Chinese traditional medicine emergency, 2018, 27(10): 1838-1841. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJZ201810045.htm
[13]	李宛蓉, 李博, 赵天易, 等. 古代灸疗医案中的灸法应用规律研究[J]. 中华中医药杂志, 2019, 34(3): 1181-1183. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201903088.htm LI W R, LI B, ZHAO T Y, et al. Study on the law of application of Moxibustion in ancient medical records[J]. Chin J Tradit Chin Med Pharm, 2019, 34(3): 1181-1183. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201903088.htm
[14]	许宝才, 邱根祥, 陈伟, 等. 雷氏补火生土法配合脐疗治疗腹泻型肠易激综合征临床研究[J]. 新中医, 2018, 50(6): 195-198. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201806058.htm XU B C, QIU G Y, CHEN Q, et al. Clinical study on the treatment of diarrhea-predominant irritable bowel syndrome (IBS) with Lei' s method of reinforcing fire and generating Earth combined with navel therapy[J]. New Chinese medicine, 2018, 50(6): 195-198. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201806058.htm
[15]	SHEN Z H, ZHU C X, QUAN Y S, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation[J]. World J Gastroenterol, 2018, 24(1): 5-14. doi: 10.3748/wjg.v24.i1.5
[16]	甄建华, 黄光瑞. 溃疡性结肠炎病因和发病机制的现代医学研究进展[J]. 世界华人消化杂志, 2019, 27(4): 245-251. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201904006.htm ZHEN J H, HUANG G R. Advances in modern medical research on the etiology and pathogenesis of ulcerative colitis[J]. World Journal of Chinese digestion, 2019, 27(4): 245-251. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201904006.htm